Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the efficacy and safety of Reduning Injection in the treatment of chikungunya fever
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical study of the efficacy and safety of Reduning Injection in the treatment of Chikungunya fever. The purpose of this study is to evaluate the efficacy and safety of Reduning Injection in the treatment of Chikungunya fever. The study uses the IWRS system to randomize the study participants, adopts the double-blind method, selects placebo control, plans to be conducted simultaneously in multiple research centers across the country, plans to include 400 study participants, and randomly assigns them to the test drug group and the placebo group at a 1:1 ratio, with 200 participants in the test drug group.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Reduning treatment group | Experimental | Redunign Injection, intravenous drip, 20 ml per dose, once a day |
|
| placebo group | Placebo Comparator | The simulant of Reduning Injection, for intravenous drip, 20 ml per time, once a day |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Reduning injection | Drug | reduning Injection, intravenous drip, 20 ml per time, once a day; |
|
| Measure | Description | Time Frame |
|---|---|---|
| Duration of symptoms | The time from the first administration of the medication until all scores for the symptoms of chikungunya fever were 0 or 1 points (if the score was 1 before the medication, it must be reduced to 0), and this remained stable for 48 hours or more | -1 day to 0 day, medication duration of 5 days ± 1 day, onset of disease 14 days ± 2 days after the onset, 90 days ± 3 days after the onset |
| Measure | Description | Time Frame |
|---|---|---|
| Recovery time of body temperature | The time required for the axillary temperature to be ≤ 37.0℃ after medication administration and to remain at this level for 24 hours or more | The subjects recorded these information in the "Subject Diary Card" during the period from -1 day to 0 day, 5 days ± 1 day after medication administration, and 14 days ± 2 days after the onset of the disease. |
Not provided
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Zhao binjiang Director of Clinical Research | Contact | +86 15300025287 | zbj0601@kanion.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The First Affiliated Hospital of Guangzhou Medical University | Guangzhou | Guangdong | 510080 | China |
Not provided
| ID | Term |
|---|---|
| D065632 | Chikungunya Fever |
| ID | Term |
|---|---|
| D018354 | Alphavirus Infections |
| D001102 | Arbovirus Infections |
| D000079426 | Vector Borne Diseases |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| C000596355 | reduning |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| The simulant of Reduning Injection | Drug | The simulant of Reduning Injection, for intravenous drip, 20 ml per time, once a day |
|
| Time for fever reduction to take effect | The time required for the first drop of 0.5℃ or more in axillary temperature after medication administration | The subjects recorded these information in the "Subject Diary Card" during the period from -1 day to 0 day, 5 days ± 1 day after medication administration, and 14 days ± 2 days after the onset of the disease. |
| The change in the integer VAS score for joint pain from baseline after 5 days of medication and 14 days after the onset of the disease | The severity of joint pain was evaluated using the Visual Analogue Scale (VAS). This method employed a 100mm long straight line, where 0 represented no joint pain symptoms and 100 represented the most intense pain. The research participants marked the corresponding position on the line that indicated their most severe level of pain. This was recorded during visits 1 to 3 in the "Research Participant Diary Card". The recording points were as follows: The first time, record the most severe pain level within 0.5 hours before the first medication administration; thereafter, record the most severe pain level once at 08:00 and 20:00 each day, with a time window of ±1 hour; if the score is 0 for more than 48 hours, there is no need to record again. | After taking the medicine for 5 days, 14 days after the onset of the disease |
| The change in the number of joint pain episodes compared to the baseline value | The researchers conducted evaluations on the study participants once each at -1 day to 0 day, 5 days ± 1 day after medication administration, and 14 days ± 2 days after the onset of the disease. |
| Time for disappearance of individual symptoms | The symptom score after medication administration was 0, and the duration required for it to remain at this score for 24 hours or longer. | -1 day to 0 day, medication duration of 5 days ± 1 day, onset of disease 14 days ± 2 days after the onset, 90 days ± 3 days after the onset |
| The rate of disappearance of individual symptoms | The symptom score after medication administration was 0, and the duration required for it to remain at this score for 24 hours or longer. | -1 day to 0 day, medication duration of 5 days ± 1 day, onset of disease 14 days ± 2 days after the onset, 90 days ± 3 days after the onset |
| The incidence rate of complications (such as bleeding, hematoma, encephalitis, myelitis, etc.) | The incidence rate of complications (such as bleeding, hematoma, encephalitis, myelitis, etc.) | From -1 day to 0 day, and up to 90 days ± 3 days after the onset of the disease, the occurrence of complications by the subjects will be recorded by the researchers. |
| The usage situation of emergency medications | The subjects should record in the "Subject Diary Card" before each use of emergency medication. | From -1 day to 0 day, within 5 days ± 1 day after medication administration, and 14 days ± 2 days after the onset of the disease. |
| D000096724 |
| Mosquito-Borne Diseases |
| D014777 | Virus Diseases |
| D014036 | Togaviridae Infections |
| D012327 | RNA Virus Infections |